Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

830 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis.
Zabotti A, De Marco G, Gossec L, Baraliakos X, Aletaha D, Iagnocco A, Gisondi P, Balint PV, Bertheussen H, Boehncke WH, Damjanov NS, de Wit M, Errichetti E, Marzo-Ortega H, Protopopov M, Puig L, Queiro R, Ruscitti P, Savage L, Schett G, Siebert S, Stamm TA, Studenic P, Tinazzi I, Van den Bosch FE, van der Helm-van Mil A, Watad A, Smolen JS, McGonagle DG. Zabotti A, et al. Among authors: smolen js. Ann Rheum Dis. 2023 Sep;82(9):1162-1170. doi: 10.1136/ard-2023-224148. Epub 2023 Jun 9. Ann Rheum Dis. 2023. PMID: 37295926 Free article.
Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.
Kerschbaumer A, Sepriano A, Bergstra SA, Smolen JS, van der Heijde D, Caporali R, Edwards CJ, Verschueren P, de Souza S, Pope JE, Takeuchi T, Hyrich KL, Winthrop KL, Aletaha D, Stamm TA, Schoones JW, Landewé RBM. Kerschbaumer A, et al. Among authors: smolen js. Ann Rheum Dis. 2023 Jan;82(1):95-106. doi: 10.1136/ard-2022-223365. Epub 2022 Nov 11. Ann Rheum Dis. 2023. PMID: 36368906
Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.
Bergstra SA, Sepriano A, Kerschbaumer A, van der Heijde D, Caporali R, Edwards CJ, Verschueren P, de Souza S, Pope JE, Takeuchi T, Hyrich KL, Winthrop KL, Aletaha D, Stamm TA, Schoones JW, Smolen JS, Landewé RBM. Bergstra SA, et al. Among authors: smolen js. Ann Rheum Dis. 2023 Jan;82(1):81-94. doi: 10.1136/ard-2022-223358. Epub 2022 Nov 21. Ann Rheum Dis. 2023. PMID: 36410794 Review.
Individual patient data meta-analysis on continued use of glucocorticoids after their initiation as bridging therapy in patients with rheumatoid arthritis.
van Ouwerkerk L, Boers M, Emery P, de Jong PH, Landewé RB, Lems W, Smolen JS, Verschueren P, Huizinga TW, Allaart CF, Bergstra SA. van Ouwerkerk L, et al. Among authors: smolen js. Ann Rheum Dis. 2023 Apr;82(4):468-475. doi: 10.1136/ard-2022-223443. Epub 2022 Dec 16. Ann Rheum Dis. 2023. PMID: 36526336 Free PMC article.
Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study.
Gossec L, Siebert S, Bergmans P, de Vlam K, Gremese E, Joven-Ibáñez B, Korotaeva TV, Lavie F, Noël W, Nurmohamed MT, Sfikakis PP, Sharaf M, Theander E, Smolen JS. Gossec L, et al. Among authors: smolen js. Ann Rheum Dis. 2023 Apr;82(4):496-506. doi: 10.1136/ard-2022-222879. Epub 2022 Dec 13. Ann Rheum Dis. 2023. PMID: 36600178 Free PMC article.
Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2022.
Winthrop KL, Isaacs JD, Mease PJ, Boumpas DT, Baraliakos X, Gottenberg JE, Siebert S, Mosca M, Basu N, Orange D, Lories R, Aletaha D, McInnes IB, Huizinga TWJ, Voll RE, Gravallese EM, Breedveld FC, Smolen JS. Winthrop KL, et al. Among authors: smolen js. Ann Rheum Dis. 2023 May;82(5):594-598. doi: 10.1136/ard-2022-223528. Epub 2023 Jan 26. Ann Rheum Dis. 2023. PMID: 36702529
Response to: Correspondence on "Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR/EULAR Boolean criteria optimal?" by Boers.
Studenic P, Aletaha D, Stamm TA, de Wit M, Lacaille D, Smolen JS, Felson D. Studenic P, et al. Among authors: smolen js. Ann Rheum Dis. 2023 Sep;82(9):e202. doi: 10.1136/ard-2022-223627. Epub 2023 Apr 20. Ann Rheum Dis. 2023. PMID: 37080713 No abstract available.
Cytokine-directed cellular cross-talk imprints synovial pathotypes in rheumatoid arthritis.
Kugler M, Dellinger M, Kartnig F, Müller L, Preglej T, Heinz LX, Simader E, Göschl L, Puchner SE, Weiss S, Shaw LE, Farlik M, Weninger W, Superti-Furga G, Smolen JS, Steiner G, Aletaha D, Kiener HP, Lewis MJ, Pitzalis C, Tosevska A, Karonitsch T, Bonelli M. Kugler M, et al. Among authors: smolen js. Ann Rheum Dis. 2023 Sep;82(9):1142-1152. doi: 10.1136/ard-2022-223396. Epub 2023 Jun 21. Ann Rheum Dis. 2023. PMID: 37344156
830 results